Nautilus Biotechnology, Inc. (NAUT): Nasdaq/NYSE listing notice — Nautilus Biotechnology receives Nasdaq bid price deficiency notice; has until Oct 28, 2025 to regain compliance.

Nautilus Biotechnology, Inc.

Received notice on May 1, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days through April 30, 2025.
Has 180 calendar days (until October 28, 2025) to regain compliance; stock continues trading.
To cure, closing bid price must be at least $1.00 for ten consecutive business days during the Compliance Period.
If not compliant, may qualify for additional 180 days by transferring to Nasdaq Capital Market and meeting other requirements.
No immediate delisting; company evaluating options but no assurance of regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Nautilus Biotechnology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)

Exact text from the filing

rice of shares of the Company’s common stock for the 30 consecutive business day period between March 19, 2025, through April 30, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until October 28, 2025 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The letter has no immediate impact on the listing o

View on SEC.gov

Browse all listing & compliance notices →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-25-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.